STOCK TITAN

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated news page for Pfizer (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pfizer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pfizer's position in the market.

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) announces its virtual-only 2024 Annual Meeting of Shareholders, providing shareholders with comparable rights to an in-person meeting. Shareholders can access the meeting online, ask questions, and vote. The meeting details and registration information are available on the company's website. Shareholders can participate in real-time discussions and submit questions in advance. Both registered and beneficial shareholders can vote during the meeting, with some beneficial owners needing to pre-register. Guests can listen to the meeting without a control number. A replay of the webcast will be available for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Pfizer Inc. announced positive top-line immunogenicity and safety data from the Phase 3 clinical trial of ABRYSVO in adults aged 18 to 59 at risk of severe RSV disease. The vaccine showed non-inferior immune response compared to older adults, with well-tolerated and consistent safety profiles. Pfizer aims to seek regulatory approval for ABRYSVO in the 18 to 59 age group, potentially addressing a significant unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary
ALTIVIA appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager. Both bring extensive experience in the chemicals industry and will contribute to ALTIVIA's growth and operational excellence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
management
Rhea-AI Summary
ViiV Healthcare, in collaboration with Pfizer and Shionogi, receives FDA approval for Dovato, the first oral, two-drug, single-tablet regimen for adolescents aged 12 and older living with HIV. The expanded indication aims to address the treatment gaps in young HIV patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
-
Rhea-AI Summary
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine has named Paychex Inc. as its 'Stock to Study' and Pfizer Inc. as its 'Undervalued Stock' in the June/July 2024 issue. Ken Zendel, CEO of the National Association of Investors Inc., emphasizes the importance of focusing on company fundamentals like earnings amidst the Reddit IPO hype.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
Pfizer Inc. (PFE) is hosting a conference call to discuss its First Quarter 2024 Performance Report on May 1, 2024. Investors and the public can access the webcast and Performance Report on Pfizer's website. The call aims to update on Pfizer's results and provide valuable insights for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences
Rhea-AI Summary
Pfizer's PREVENAR 20® Receives Marketing Authorization in the EU for Broad Serotype Coverage in Children, Boosting Protection Against Pneumococcal Disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
-
Rhea-AI Summary
Pfizer's Phase 3 ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab shows significant improvement in overall survival, progression free survival, and overall response rate for patients with relapsed/refractory diffuse large B-cell lymphoma. The study results are promising, potentially leading to an eighth indication for ADCETRIS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
-
Rhea-AI Summary
ViiV Healthcare, in collaboration with Pfizer Inc. and Shionogi Limited, announced positive data from the LATITUDE phase III trial for Cabenuva, a long-acting injectable ART for HIV. The interim analysis showed superior efficacy in maintaining viral load suppression compared to daily oral therapy, with key secondary endpoints favoring the new regimen. The study, conducted by ACTG, included diverse participants and was funded by NIAID.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
none
Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) will host a webcast with Mikael Dolsten, discussing Pfizer's Research and Development at the Leerink Partners Global Biopharma Conference 2024. The webcast will be available on the Pfizer website, with a transcript and replay accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
conferences
Pfizer Inc.

NYSE:PFE

PFE Rankings

PFE Stock Data

149.15B
5.64B
0.05%
69.96%
1.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About PFE

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.